Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Pharma-Amlodipine (02469030), Pharma-Amlodipine (02469049). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
AMLODIPINE
Form:
24 of 24 products shown
13 general benefit · 1 Limited Use · 10 not a benefit
Other products in the same Health Canada class (C08CA) — coverage varies; not interchangeable
Felodipine (Plendil): general benefit, Not a benefit
Nifedipine (Nifedipine): general benefit, Not a benefit
PDP-Amlodipine · DIN 02484706 · 1mg/mL · Oral Sol
Limited Use — Reason for Use code 645, 706 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 645, 706 required
Write on scriptLU code 645, 706 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 645, 706
Reason for Use code 645
For patients unable to swallow or tolerate oral solid dosage forms of amlodipine.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 706
For pediatric patients (less than 18 years of age) where the appropriate dose cannot be achieved using a listed solid oral dosage form of amlodipine.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
PDP-Amlodipine · DIN 02484706
Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 2023-04-28
Health Canada: Marketed since 2019-08-28 · brand PDP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Solution · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 1 MG/ML · company Pendopharm division of pharmascience inc · schedule Prescription
PDP-Amlodipine: Formulary list price $1.1667/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.1667 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97499 · Verify on the e-Formulary ↗ (DIN 02484706)
Source record
DIN 02484706: PDP-Amlodipine
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240400176; group id 274; item number 0566; lccId 00369; manufacturer id PEN
Source form: Oral Sol; strength: 1mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.1667; ministry $1.1667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484706
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97499
Shortage status: resolved shortage (ended 2023-08-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484706
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Amlodipine · DIN 02419564 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Amlodipine · DIN 02419564
Manufacturer: Accord Healthcare Inc.; listing date 2019-01-31
Daily cost (source): $0.1343
Health Canada: Marketed since 2022-09-13 · brand ACH-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Accord healthcare inc · schedule Prescription
Ach-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90418 · Verify on the e-Formulary ↗ (DIN 02419564)
Source record
DIN 02419564: Ach-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419564
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90418Interchangeable products
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2023-09-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419564
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Amlodipine · DIN 02297485 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Amlodipine · DIN 02297485
Manufacturer: Teva Canada Limited; listing date 2009-09-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2024-11-08 · brand TEVA-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Teva canada limited · schedule Prescription
Act Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78283 · Verify on the e-Formulary ↗ (DIN 02297485)
Source record
DIN 02297485: Act Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297485
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78283Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297485
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02331284 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02331284
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Daily cost (source): $0.1343
Health Canada: Marketed since 2022-09-01 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Sanis health inc · schedule Prescription
Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81699 · Verify on the e-Formulary ↗ (DIN 02331284)
Source record
DIN 02331284: Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02331284
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81699Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2017-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02331284
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02385791 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02385791
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2016-09-28 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87141 · Verify on the e-Formulary ↗ (DIN 02385791)
Source record
DIN 02385791: Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385791
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87141Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385791
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02429217 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Amlodipine · DIN 02429217
Manufacturer: Jamp Pharma Corporation; listing date 2015-01-28
Daily cost (source): $0.1343
Health Canada: Marketed since 2021-02-17 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91365 · Verify on the e-Formulary ↗ (DIN 02429217)
Source record
DIN 02429217: Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429217
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91365Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429217
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Amlodipine · DIN 02273373 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Amlodipine · DIN 02273373
Manufacturer: Apotex Inc.; listing date 2009-09-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2009-07-09 · brand APO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Apotex inc · schedule Prescription
Apo-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75886 · Verify on the e-Formulary ↗ (DIN 02273373)
Source record
DIN 02273373: Apo-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02273373
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75886Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2021-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02273373
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Amlodipine · DIN 02397072 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Amlodipine · DIN 02397072
Manufacturer: Auro Pharma Inc.; listing date 2013-04-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2013-02-12 · brand AURO-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Auro pharma inc · schedule Prescription
Auro-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88206 · Verify on the e-Formulary ↗ (DIN 02397072)
Source record
DIN 02397072: Auro-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397072
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88206Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2025-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02397072
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Amlodipine · DIN 02357194 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Amlodipine · DIN 02357194
Manufacturer: Jamp Pharma Corporation; listing date 2012-02-29
Daily cost (source): $0.1343
Health Canada: Marketed since 2025-04-04 · brand JAMP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84232 · Verify on the e-Formulary ↗ (DIN 02357194)
Source record
DIN 02357194: Jamp-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357194
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84232Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357194
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Amlodipine · DIN 02468026 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amlodipine · DIN 02468026
Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2017-12-14 · brand M-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Mantra pharma inc · schedule Prescription
M-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95638 · Verify on the e-Formulary ↗ (DIN 02468026)
Source record
DIN 02468026: M-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MAT
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468026
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95638Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02468026
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Amlodipine Tablets · DIN 02371715 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Amlodipine Tablets · DIN 02371715
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Daily cost (source): $0.1343
Health Canada: Marketed since 2021-08-06 · brand MAR-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Amlodipine Tablets: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85685 · Verify on the e-Formulary ↗ (DIN 02371715)
Source record
DIN 02371715: Mar-Amlodipine Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MAR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371715
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85685Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2018-09-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371715
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Amlodipine · DIN 02362651 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Amlodipine · DIN 02362651
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2011-08-04
Daily cost (source): $0.1343
Health Canada: Marketed since 2011-02-16 · brand MINT-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84766 · Verify on the e-Formulary ↗ (DIN 02362651)
Source record
DIN 02362651: Mint-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02362651
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84766Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2018-01-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02362651
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Amlodipine · DIN 02272113 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Amlodipine · DIN 02272113
Manufacturer: Mylan Pharmaceuticals ULC; listing date 2009-09-30
Daily cost (source): $0.1343
Health Canada: Marketed since 2010-01-15 · brand MYLAN-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5.0 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75765 · Verify on the e-Formulary ↗ (DIN 02272113)
Source record
DIN 02272113: Mylan-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id MYL
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02272113
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75765Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
NRA-Amlodipine · DIN 02476460 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: resolved shortage (ended 2018-02-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272113
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Amlodipine · DIN 02476460 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Amlodipine · DIN 02476460
Manufacturer: Nora Pharma; listing date 2020-08-28
Daily cost (source): $0.1343
Health Canada: Marketed since 2023-12-05 · brand NRA-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Nora pharma inc · schedule Prescription
NRA-Amlodipine: Formulary list price $0.1343/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1343 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96695 · Verify on the e-Formulary ↗ (DIN 02476460)
Source record
DIN 02476460: NRA-Amlodipine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400120; group id 275; item number 0568; lccId None; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1343; ministry $0.1343
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476460
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96695Interchangeable products
Ach-Amlodipine · DIN 02419564 · $0.1343
Act Amlodipine · DIN 02297485 · $0.1343
Amlodipine · DIN 02331284 · $0.1343
Amlodipine · DIN 02385791 · $0.1343
Amlodipine · DIN 02429217 · $0.1343
Apo-Amlodipine · DIN 02273373 · $0.1343
Auro-Amlodipine · DIN 02397072 · $0.1343
Gd-Amlodipine · DIN 02280132 · $0.1343
Jamp-Amlodipine · DIN 02357194 · $0.1343
M-Amlodipine · DIN 02468026 · $0.1343
Mar-Amlodipine Tablets · DIN 02371715 · $0.1343
Mint-Amlodipine · DIN 02362651 · $0.1343
Mylan-Amlodipine · DIN 02272113 · $0.1343
Norvasc · DIN 00878928 · $0.1343
PMS-Amlodipine · DIN 02284065 · $0.1343
PRZ-Amlodipine · DIN 02522519 · $0.1343
Ran-Amlodipine · DIN 02321858 · $0.1343
Ratio-Amlodipine · DIN 02259605 · $0.1343
Sandoz Amlodipine · DIN 02284383 · $0.1343
Septa-Amlodipine · DIN 02357712 · $0.1343
Teva-Amlodipine · DIN 02250497 · $0.1343
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02476460
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ach-Amlodipine · DIN 02419556 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ach-Amlodipine · DIN 02419556
Manufacturer: Accord Healthcare Inc.; listing date 2025-09-29
Health Canada: Marketed since 2023-02-22 · brand ACH-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Accord healthcare inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90417 · Verify on the e-Formulary ↗ (DIN 02419556)
Source record
DIN 02419556: Ach-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id ACH
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02419556
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90417Interchangeable products
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended 2024-08-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02419556
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02385783 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amlodipine · DIN 02385783
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-02-28
Health Canada: Marketed since 2016-09-28 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87140 · Verify on the e-Formulary ↗ (DIN 02385783)
Source record
DIN 02385783: Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SIV
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385783
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87140Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385783
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02478587 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amlodipine · DIN 02478587
Manufacturer: Sanis Health Inc.; listing date 2025-03-31
Health Canada: Marketed since 2023-04-07 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96905 · Verify on the e-Formulary ↗ (DIN 02478587)
Source record
DIN 02478587: Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SAI
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478587
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96905Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02478587
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Amlodipine · DIN 02492199 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amlodipine · DIN 02492199
Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31
Health Canada: Marketed since 2026-08-11 · brand AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98218 · Verify on the e-Formulary ↗ (DIN 02492199)
Source record
DIN 02492199: Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id JPC
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492199
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98218Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02492199
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Amlodipine · DIN 02357186 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Amlodipine · DIN 02357186
Manufacturer: Jamp Pharma Corporation; listing date 2025-06-30
Health Canada: Marketed since 2021-04-21 · brand JAMP-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84231 · Verify on the e-Formulary ↗ (DIN 02357186)
Source record
DIN 02357186: Jamp-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id JPC
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357186
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84231Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended 2021-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02357186
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Amlodipine · DIN 02468018 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Amlodipine · DIN 02468018
Manufacturer: Mantra Pharma Inc.; listing date 2025-04-30
Health Canada: Marketed since 2018-03-07 · brand M-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Mantra pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95637 · Verify on the e-Formulary ↗ (DIN 02468018)
Source record
DIN 02468018: M-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id MAT
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02468018
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95637Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02468018
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Amlodipine · DIN 02371707 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Amlodipine · DIN 02371707
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-03-31
Health Canada: Marketed since 2021-08-06 · brand MAR-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85684 · Verify on the e-Formulary ↗ (DIN 02371707)
Source record
DIN 02371707: Mar-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id MAR
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371707
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85684Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended 2019-09-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02371707
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Amlodipine · DIN 02295148 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Amlodipine · DIN 02295148
Manufacturer: Pharmascience Inc.; listing date 2025-02-28
Health Canada: Marketed since 2009-07-15 · brand PMS-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78046 · Verify on the e-Formulary ↗ (DIN 02295148)
Source record
DIN 02295148: PMS-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id PMS
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295148
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78046Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: resolved shortage (ended 2019-11-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295148
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PRZ-Amlodipine · DIN 02522500 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PRZ-Amlodipine · DIN 02522500
Manufacturer: Pharmaris Canada Inc.; listing date 2026-01-30
Health Canada: Marketed since 2022-09-21 · brand PRZ-AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Pharmaris canada inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101162 · Verify on the e-Formulary ↗ (DIN 02522500)
Source record
DIN 02522500: PRZ-Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id PRZ
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522500
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101162Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
Sandoz Amlodipine · DIN 02330474 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02522500
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Amlodipine · DIN 02330474 · 2.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Amlodipine · DIN 02330474
Manufacturer: Sandoz Canada Inc.; listing date 2024-12-30
Health Canada: Marketed since 2009-08-05 · brand SANDOZ AMLODIPINE · ATC C08CA01 AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 2.5 MG · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81620 · Verify on the e-Formulary ↗ (DIN 02330474)
Source record
DIN 02330474: Sandoz Amlodipine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240400179; group id 275; item number 0567; lccId None; manufacturer id SDZ
Source form: Tab; strength: 2.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.3328; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330474
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81620Interchangeable products
Ach-Amlodipine · DIN 02419556 · not recorded
Amlodipine · DIN 02385783 · not recorded
Amlodipine · DIN 02478587 · not recorded
Amlodipine · DIN 02492199 · not recorded
Jamp-Amlodipine · DIN 02357186 · not recorded
M-Amlodipine · DIN 02468018 · not recorded
Mar-Amlodipine · DIN 02371707 · not recorded
Norvasc · DIN 00878901 · not recorded
PMS-Amlodipine · DIN 02295148 · not recorded
PRZ-Amlodipine · DIN 02522500 · not recorded
Shortage status: resolved shortage (ended 2023-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330474
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered
Matched class: 24:04 Cardiac Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL
Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL
24:00 CARDIOVASCULAR DRUGS
· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab
· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04
and 9 more
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered
Matched class: 24:06 Antilipemic Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM
Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN
24:00 CARDIOVASCULAR DRUGS
· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06
and 4 more
· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08
and 34 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monographAZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monographBENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monographCANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monographCANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monographCHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monographCILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monographCLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monographDILTIAZEM HCL · General benefit (91), Listed, not a benefit (2)
1 INDICATIONS
AA-DILTIAZ (diltiazem hydrochloride) is indicated for:
• Angina
▪ AA-DILTIAZ (diltiazem hydrochloride) tablets may be used in the management of angina
resulting from coronary artery spasm.
▪ AA-DILTIAZ tablets are indicated for the management of chronic stable angina (effort-
associated angina) without evidence of vasospasm in patients who remain
symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who
cannot tolerate those agents.
PM: https://pdf.hres.ca/dpd_pm/00082380.PDF; date DEC 31, 1988; DIN 00771376; fetched 2026-09-10
Product monographENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
and 20 more
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
Combination of NORVASC with a diuretic, a beta-blocking agent, or an angiotensin
converting enzyme inhibitor has been found to be compatible and showed additive
antihypertensive effect.
• Chronic Stable Angina
NORVASC is indicated for the management of chronic stable angina (effort-associated
angina) in patients who remain symptomatic despite adequate doses of beta-blockers
and/or organic nitrates or who cannot tolerate those agents.
NORVASC may be tried in combination with beta-blockers in chronic stable angina in
patients with normal ventricular function. When such concomitant therapy is introduced,
care must be taken to monitor blood pressure closely since hypotension can occur from the
combined effects of the drugs.
1.1 Pediatrics
Pediatrics (6 – 17 years of age): Based on the data submitted and reviewed by Health Canada,
the safety and efficacy of NORVASC in pediatric patients has been established. Therefore,
Health Canada has aut…
https://pdf.hres.ca/dpd_pm/00071908.PDF
PM date: AUG 02, 2023
Source product: NORVASC; DIN 00878928; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
CADUET (amlodipine besylate/atorvastatin calcium) is indicated in patients for whom treatment with
both amlodipine and atorvastatin is appropriate, specifically, patients at cardiovascular risk.
CADUET is not for initial therapy. The dose of CADUET should be determined by the titration of
individual components (see 4 DOSAGE AND ADMINISTRATION).
1.1 Pediatrics
Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CADUET in
pediatric patients has not been established; therefore, Health Canada has not authorized an indication
for pediatric use. However, there have been studies using amlodipine or atorvastatin only in pediatrics
(see 7.1.3 Pediatrics).
1.2 Geriatrics
Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the
geriatric population is associated with differences in safety or effectiveness (see 7.1.4 Geriatrics).
https://pdf.hres.ca/dpd_pm/00081162.PDF
PM date: JUL 23, 2025
Source product: CADUET; DIN 02273233; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
VIACORAM (perindopril arginine and amlodipine) is indicated for:
• The treatment of mild to moderate essential hypertension in patients for whom combination therapy
is appropriate.
• VIACORAM 3.5 mg/2.5 mg is indicated for initial therapy in patients with mild to moderate essential
hypertension.
• VIACORAM is not indicated for switching therapy from the individual drugs currently on the market
(perindopril as erbumine or arginine salt, amlodipine) (see 4 Dosage and Administration ).
1.1. Pediatrics
Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not
authorized an indication for pediatric use.
1.2. Geriatrics
Geriatrics (> 65 years): VIACORAM is not indicated for the initiation of treatment in elderly patients. There
is no sufficient clinical experience to justify the use in the elderly (> 65 years).
https://pdf.hres.ca/dpd_pm/00085937.PDF
PM date: 2026-08-27
Source product: VIACORAM; DIN 02451530; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
TWYNSTA (telmisartan/amlodipine besylate) is indicated for:
• treatment of mild to moderate essential hypertension for whom combination therapy
with telmisartan and amlodipine is appropriate.
TWYNSTA is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION).
1.1 Pediatrics
• Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health
Canada, the safety and efficacy of TWYNSTA in pediatric patients has not been
established; therefore, Health Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
• Geriatrics (> 65 years of age): No dose adjustment is necessary for geriatric patients. It
should be recognized, however, that greater sensitivity in some older individuals cannot
be ruled out.
https://pdf.hres.ca/dpd_pm/00077924.PDF
PM date: AUG 11, 2011
Source product: TWYNSTA; DIN 02371022; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Other review policies
For Ach-Amlodipine, Amlodipine, Jamp-Amlodipine, M-Amlodipine, Mar-Amlodipine, PMS-Amlodipine, PRZ-Amlodipine, Sandoz Amlodipine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.